Business Standard

SEC recommendation in accordance with guidelines: Biocon Biologics

The company said its product approvals are backed by science and clinical data

SAT stays Biocon insider trading order
Premium

The company said it condemns all acts of corruption and bribery and is cooperating with the investigating agency.

Sohini Das Mumbai
Biocon Biologics not only denied allegations of bribery, but said that the rationale for waiving phase-3 clinical trials for its Insulin Aspart injection was based on Indian regulatory guidance.

The company said its product approvals are backed by science and clinical data, and the rationale for waiver was based on the Similar Biologics Guidelines, 2016, and New Drugs and Clinical Trials, 2019.

“The guidelines provide a framework for waiver of phase-3 clinical trials to be conducted in India based on a commitment to undertake a phase-4 trial, the design of which should be approved by the Central Licencing Authority. In line with

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in